Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease.
Eur J Neurol
; 21(2): 357-60, 2014 Feb.
Article
en En
| MEDLINE
| ID: mdl-23790011
ABSTRACT
BACKGROUND AND PURPOSE:
Fatigue is a common symptom of Parkinson's disease (PD), often considered by patients as one of the most disabling PD symptoms with significant impact on quality of life. Our aim was to assess the benefits of rasagiline treatment on fatigue in early PD patients.METHODS:
In this sub-study of ADAGIO (N Engl J Med 2009; 361 1268), 1105 untreated PD patients were randomized to receive rasagiline 1 mg/day (n = 270) or 2 mg/day (n = 277) or placebo (n = 558) for 36 weeks. The 16-item Parkinson Fatigue Scale (PFS) was assessed at baseline and at week 36/early withdrawal visit. Changes from baseline to last observed visit for each rasagiline group were compared with placebo using ancova.RESULTS:
Mean baseline PFS score was 2.2 ± 0.9 units. At 36 weeks, patients receiving placebo showed greater progression of symptoms (0.17 units) from baseline in PFS scores compared with the 1 mg/day (0.03 units) and 2 mg/day rasagiline groups (-0.02 units); the difference versus placebo was significant for both rasagiline groups (P < 0.01).CONCLUSIONS:
Symptoms of fatigue can be detected in patients with early PD and progressively worsen over time. Rasagiline was associated with significantly less progression of fatigue compared with placebo over a 9-month period.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedad de Parkinson
/
Fatiga
/
Indanos
/
Inhibidores de la Monoaminooxidasa
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
Aspecto:
Patient_preference
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Eur J Neurol
Asunto de la revista:
NEUROLOGIA
Año:
2014
Tipo del documento:
Article
País de afiliación:
Italia